Table 2 Open in new tab Comparison of...

Variable	non-CR (n = 29)	pCR (n = 23)	P-value
Age (years) (n = 52)	65 (55–72)	60 (56–68)	0.926^*
Gender	Female	13 (45%)	5 (22%)	0.082#
Male	16 (55%)	18 (78%)
BMI (Kg/m²) (n = 52)	23.0 (21.1–27.0)	24.3 (22.5–26.6)	0.191^*
RCS Charlson-Index	0	1 (3%)	1 (4%)	0.723#
1	12 (41%)	13 (57%)
2	9 (31%)	5 (22%)
≥3	7 (24%)	4 (17%)
uT-Stage	T1	2 (7%)	2 (9%)	0.767#
T2	2 (7%)	4 (17%)
T3	18 (62%)	11 (48%)
T4	3 (10%)	3 (13%)
NA	4 (14%)	3 (13%)
uN-Stage	uN-	3 (10%)	4 (17%)	0.675#
uN+	22 (76%)	15 (65%)
NA	4 (14%)	4 (17%)
cM-Stage	cM0	23 (79%)	21 (91%)	0.234#
cMX/1	6 (21%)	2 (9%)
Grading	GX	11 (38%)	12 (52%)	0.362#
G1	0 (0%)	1 (4%)
G2	10 (34%)	7 (30%)
G3	8 (28%)	3 (13%)
Neoadjuvant Chemotherapy	2 (7%)	0 (0%)	0.199#
Thereof: % FLOT	1 (50%)	0 (0%)
Neoadjuvant Chemoradiation	27 (93%)	23 (100%)
Thereof: % CROSS	23 (85%)	19 (83%)
Radiation Dosage (Gy) (n = 47)	41.1 (41.1–41.4)	41.1 (41.1–41.4)	0.558^*
Premature discontinuation of neoadjuvant treatment	2 (7%)	0 (0%)	0.199#
Days from end of neoadjuvant treatment to surgery (n = 51)	60 (45.5–84)	46.5 (37.75–59.75)	0.069^*
RECIST 1.1	CR/PR	21 (72%)	18 (78%)	0.629#
Procedure	2-Field-Esophagectomy	25 (86%)	23 (100%)	0.064#
3-Field-Esophagectomy	4 (14%)	0 (0%)
Transhiatal-extended gastrectomy	0 (0%)	0 (0%)
Esophagogastrectomy	0 (0%)	0 (0%)
CCI (n = 52)	40.6 (26.1–60.2)	22.6 (0–62.6)	0.149^*
Length of Hospital Stay (days) (n = 52)	23 (16–27.5)	16 (13–24)	0.069^*
Pathological T-Stage	ypT0	4 (14%)	23 (100%)	<0.001#
ypT1	6 (21%)	0 (0%)
ypT2	10 (34%)	0 (0%)
ypT3	8 (28%)	0 (0%)
ypT4	1 (3%)	0 (0%)
Pathological N-Stage	ypN0	15 (52%)	23 (100%)	<0.001#
ypN1	11 (38%)	0 (0%)
ypN2	3 (10%)	0 (0%)
Tumor regression in lymphnodes in pCR-patients	(LN-/Reg+)/Grade A	NA	7 (30%)	NA
(LN-/Reg-)	NA	16 (70%)
Postneoadjuvant M-Stage	yM0	27 (93%)	23 (100%)	0.199#
ypM1	2 (7%)	0 (0%)
R-Status	R0	25 (86%)	23 (100%)	0.064#
R1	4 (14%)	0 (0%)
Postoperative UICC-Stage	UICC-Stage 0	0 (0%)	23 (100%)	<0.001#
UICC-Stage I	7 (24%)	0 (0%)
UICC-Stage II	11 (38%)	0 (0%)
UICC-Stage III	8 (28%)	0 (0%)
UICC-Stage IV	3 (10%)	0 (0%)
Histopathologic Regression	Grade 1a - No residual tumor	4 (14%)	23 (100%)	<0.001#
Grade 1b – Subtotal regression (<10% residual tumor)	12 (41%)	0 (0%)
Grade 2 – partial regression (10–50% residual tumor)	6 (21%)	0 (0%)
Grade 3 – no regression (>50% residual tumor)	6 (21%)	0 (0%)
Grade of regression not assessed	1 (3%)	0 (0%)

Variable

non-CR (n = 29)

pCR (n = 23)

P-value

Age (years) (n = 52)

65 (55–72)

60 (56–68)

0.926^*

Gender

Female

13 (45%)

5 (22%)

0.082#

Male

16 (55%)

18 (78%)

BMI (Kg/m²) (n = 52)

23.0 (21.1–27.0)

24.3 (22.5–26.6)

0.191^*

RCS Charlson-Index

1 (3%)

1 (4%)

0.723#

12 (41%)

13 (57%)

9 (31%)

5 (22%)

≥3

7 (24%)

4 (17%)

uT-Stage

2 (7%)

2 (9%)

0.767#

2 (7%)

4 (17%)

18 (62%)

11 (48%)

3 (10%)

3 (13%)

4 (14%)

3 (13%)

uN-Stage

uN-

3 (10%)

4 (17%)

0.675#

uN+

22 (76%)

15 (65%)

4 (14%)

4 (17%)

cM-Stage

cM0

23 (79%)

21 (91%)

0.234#

cMX/1

6 (21%)

2 (9%)

Grading

11 (38%)

12 (52%)

0.362#

0 (0%)

1 (4%)

10 (34%)

7 (30%)

8 (28%)

3 (13%)

Neoadjuvant Chemotherapy

2 (7%)

0 (0%)

0.199#

Thereof: % FLOT

1 (50%)

0 (0%)

Neoadjuvant Chemoradiation

27 (93%)

23 (100%)

Thereof: % CROSS

23 (85%)

19 (83%)

Radiation Dosage (Gy) (n = 47)

41.1 (41.1–41.4)

0.558^*

Premature discontinuation of neoadjuvant treatment

2 (7%)

0 (0%)

0.199#

Days from end of neoadjuvant treatment to surgery (n = 51)

60 (45.5–84)

46.5 (37.75–59.75)

0.069^*

RECIST 1.1

CR/PR

21 (72%)

18 (78%)

0.629#

Procedure

2-Field-Esophagectomy

25 (86%)

23 (100%)

0.064#

3-Field-Esophagectomy

4 (14%)

0 (0%)

Transhiatal-extended gastrectomy

0 (0%)

Esophagogastrectomy

0 (0%)

CCI (n = 52)

40.6 (26.1–60.2)

22.6 (0–62.6)

0.149^*

Length of Hospital Stay (days) (n = 52)

23 (16–27.5)

16 (13–24)

0.069^*

Pathological T-Stage

ypT0

4 (14%)

23 (100%)

<0.001#

ypT1

6 (21%)

0 (0%)

ypT2

10 (34%)

0 (0%)

ypT3

8 (28%)

0 (0%)

ypT4

1 (3%)

0 (0%)

Pathological N-Stage

ypN0

15 (52%)

23 (100%)

<0.001#

ypN1

11 (38%)

0 (0%)

ypN2

3 (10%)

0 (0%)

Tumor regression in lymphnodes in pCR-patients

(LN-/Reg+)/Grade A

7 (30%)

(LN-/Reg-)

16 (70%)

Postneoadjuvant M-Stage

yM0

27 (93%)

23 (100%)

0.199#

ypM1

2 (7%)

0 (0%)

R-Status

25 (86%)

23 (100%)

0.064#

4 (14%)

0 (0%)

Postoperative UICC-Stage

UICC-Stage 0

0 (0%)

23 (100%)

<0.001#

UICC-Stage I

7 (24%)

0 (0%)

UICC-Stage II

11 (38%)

0 (0%)

UICC-Stage III

8 (28%)

0 (0%)

UICC-Stage IV

3 (10%)

0 (0%)

Histopathologic Regression

Grade 1a - No residual tumor

4 (14%)

23 (100%)

<0.001#

Grade 1b – Subtotal regression (<10% residual tumor)

12 (41%)

0 (0%)

Grade 2 – partial regression (10–50% residual tumor)

6 (21%)

0 (0%)

Grade 3 – no regression (>50% residual tumor)

6 (21%)

0 (0%)

Grade of regression not assessed

1 (3%)

0 (0%)

Variable	non-CR (n = 29)	pCR (n = 23)	P-value
Age (years) (n = 52)	65 (55–72)	60 (56–68)	0.926^*
Gender	Female	13 (45%)	5 (22%)	0.082#
Male	16 (55%)	18 (78%)
BMI (Kg/m²) (n = 52)	23.0 (21.1–27.0)	24.3 (22.5–26.6)	0.191^*
RCS Charlson-Index	0	1 (3%)	1 (4%)	0.723#
1	12 (41%)	13 (57%)
2	9 (31%)	5 (22%)
≥3	7 (24%)	4 (17%)
uT-Stage	T1	2 (7%)	2 (9%)	0.767#
T2	2 (7%)	4 (17%)
T3	18 (62%)	11 (48%)
T4	3 (10%)	3 (13%)
NA	4 (14%)	3 (13%)
uN-Stage	uN-	3 (10%)	4 (17%)	0.675#
uN+	22 (76%)	15 (65%)
NA	4 (14%)	4 (17%)
cM-Stage	cM0	23 (79%)	21 (91%)	0.234#
cMX/1	6 (21%)	2 (9%)
Grading	GX	11 (38%)	12 (52%)	0.362#
G1	0 (0%)	1 (4%)
G2	10 (34%)	7 (30%)
G3	8 (28%)	3 (13%)
Neoadjuvant Chemotherapy	2 (7%)	0 (0%)	0.199#
Thereof: % FLOT	1 (50%)	0 (0%)
Neoadjuvant Chemoradiation	27 (93%)	23 (100%)
Thereof: % CROSS	23 (85%)	19 (83%)
Radiation Dosage (Gy) (n = 47)	41.1 (41.1–41.4)	41.1 (41.1–41.4)	0.558^*
Premature discontinuation of neoadjuvant treatment	2 (7%)	0 (0%)	0.199#
Days from end of neoadjuvant treatment to surgery (n = 51)	60 (45.5–84)	46.5 (37.75–59.75)	0.069^*
RECIST 1.1	CR/PR	21 (72%)	18 (78%)	0.629#
Procedure	2-Field-Esophagectomy	25 (86%)	23 (100%)	0.064#
3-Field-Esophagectomy	4 (14%)	0 (0%)
Transhiatal-extended gastrectomy	0 (0%)	0 (0%)
Esophagogastrectomy	0 (0%)	0 (0%)
CCI (n = 52)	40.6 (26.1–60.2)	22.6 (0–62.6)	0.149^*
Length of Hospital Stay (days) (n = 52)	23 (16–27.5)	16 (13–24)	0.069^*
Pathological T-Stage	ypT0	4 (14%)	23 (100%)	<0.001#
ypT1	6 (21%)	0 (0%)
ypT2	10 (34%)	0 (0%)
ypT3	8 (28%)	0 (0%)
ypT4	1 (3%)	0 (0%)
Pathological N-Stage	ypN0	15 (52%)	23 (100%)	<0.001#
ypN1	11 (38%)	0 (0%)
ypN2	3 (10%)	0 (0%)
Tumor regression in lymphnodes in pCR-patients	(LN-/Reg+)/Grade A	NA	7 (30%)	NA
(LN-/Reg-)	NA	16 (70%)
Postneoadjuvant M-Stage	yM0	27 (93%)	23 (100%)	0.199#
ypM1	2 (7%)	0 (0%)
R-Status	R0	25 (86%)	23 (100%)	0.064#
R1	4 (14%)	0 (0%)
Postoperative UICC-Stage	UICC-Stage 0	0 (0%)	23 (100%)	<0.001#
UICC-Stage I	7 (24%)	0 (0%)
UICC-Stage II	11 (38%)	0 (0%)
UICC-Stage III	8 (28%)	0 (0%)
UICC-Stage IV	3 (10%)	0 (0%)
Histopathologic Regression	Grade 1a - No residual tumor	4 (14%)	23 (100%)	<0.001#
Grade 1b – Subtotal regression (<10% residual tumor)	12 (41%)	0 (0%)
Grade 2 – partial regression (10–50% residual tumor)	6 (21%)	0 (0%)
Grade 3 – no regression (>50% residual tumor)	6 (21%)	0 (0%)
Grade of regression not assessed	1 (3%)	0 (0%)

Table 2

Open in new tab

Comparison of ESCC-patients with neoadjuvant treatment

Variable		non-CR (n = 29)	pCR (n = 23)	P-value
Age (years) (n = 52)		65 (55–72)	60 (56–68)	0.926^*
Gender	Female	13 (45%)	5 (22%)	0.082#
Gender	Male	16 (55%)	18 (78%)	0.082#
BMI (Kg/m²) (n = 52)		23.0 (21.1–27.0)	24.3 (22.5–26.6)	0.191^*
RCS Charlson-Index	0	1 (3%)	1 (4%)	0.723#
	1	12 (41%)	13 (57%)
	2	9 (31%)	5 (22%)
	≥3	7 (24%)	4 (17%)
uT-Stage	T1	2 (7%)	2 (9%)	0.767#
	T2	2 (7%)	4 (17%)
	T3	18 (62%)	11 (48%)
	T4	3 (10%)	3 (13%)
	NA	4 (14%)	3 (13%)
uN-Stage	uN-	3 (10%)	4 (17%)	0.675#
	uN+	22 (76%)	15 (65%)
	NA	4 (14%)	4 (17%)
cM-Stage	cM0	23 (79%)	21 (91%)	0.234#
cM-Stage	cMX/1	6 (21%)	2 (9%)	0.234#
Grading	GX	11 (38%)	12 (52%)	0.362#
	G1	0 (0%)	1 (4%)
	G2	10 (34%)	7 (30%)
	G3	8 (28%)	3 (13%)
Neoadjuvant Chemotherapy		2 (7%)	0 (0%)	0.199#
Thereof: % FLOT		1 (50%)	0 (0%)
Neoadjuvant Chemoradiation		27 (93%)	23 (100%)
Thereof: % CROSS		23 (85%)	19 (83%)
Radiation Dosage (Gy) (n = 47)		41.1 (41.1–41.4)	41.1 (41.1–41.4)	0.558^*
Premature discontinuation of neoadjuvant treatment		2 (7%)	0 (0%)	0.199#
Days from end of neoadjuvant treatment to surgery (n = 51)		60 (45.5–84)	46.5 (37.75–59.75)	0.069^*
RECIST 1.1	CR/PR	21 (72%)	18 (78%)	0.629#
Procedure	2-Field-Esophagectomy	25 (86%)	23 (100%)	0.064#
	3-Field-Esophagectomy	4 (14%)	0 (0%)
	Transhiatal-extended gastrectomy	0 (0%)	0 (0%)
	Esophagogastrectomy	0 (0%)	0 (0%)
CCI (n = 52)		40.6 (26.1–60.2)	22.6 (0–62.6)	0.149^*
Length of Hospital Stay (days) (n = 52)		23 (16–27.5)	16 (13–24)	0.069^*
Pathological T-Stage	ypT0	4 (14%)	23 (100%)	<0.001#
	ypT1	6 (21%)	0 (0%)
	ypT2	10 (34%)	0 (0%)
	ypT3	8 (28%)	0 (0%)
	ypT4	1 (3%)	0 (0%)
Pathological N-Stage	ypN0	15 (52%)	23 (100%)	<0.001#
	ypN1	11 (38%)	0 (0%)
	ypN2	3 (10%)	0 (0%)
Tumor regression in lymphnodes in pCR-patients	(LN-/Reg+)/Grade A	NA	7 (30%)	NA
Tumor regression in lymphnodes in pCR-patients	(LN-/Reg-)	NA	16 (70%)	NA
Postneoadjuvant M-Stage	yM0	27 (93%)	23 (100%)	0.199#
Postneoadjuvant M-Stage	ypM1	2 (7%)	0 (0%)	0.199#
R-Status	R0	25 (86%)	23 (100%)	0.064#
R-Status	R1	4 (14%)	0 (0%)	0.064#
Postoperative UICC-Stage	UICC-Stage 0	0 (0%)	23 (100%)	<0.001#
	UICC-Stage I	7 (24%)	0 (0%)
	UICC-Stage II	11 (38%)	0 (0%)
	UICC-Stage III	8 (28%)	0 (0%)
	UICC-Stage IV	3 (10%)	0 (0%)
Histopathologic Regression	Grade 1a - No residual tumor	4 (14%)	23 (100%)	<0.001#
	Grade 1b – Subtotal regression (<10% residual tumor)	12 (41%)	0 (0%)
	Grade 2 – partial regression (10–50% residual tumor)	6 (21%)	0 (0%)
	Grade 3 – no regression (>50% residual tumor)	6 (21%)	0 (0%)
	Grade of regression not assessed	1 (3%)	0 (0%)

Variable		non-CR (n = 29)	pCR (n = 23)	P-value
Age (years) (n = 52)		65 (55–72)	60 (56–68)	0.926^*
Gender	Female	13 (45%)	5 (22%)	0.082#
Gender	Male	16 (55%)	18 (78%)	0.082#
BMI (Kg/m²) (n = 52)		23.0 (21.1–27.0)	24.3 (22.5–26.6)	0.191^*
RCS Charlson-Index	0	1 (3%)	1 (4%)	0.723#
	1	12 (41%)	13 (57%)
	2	9 (31%)	5 (22%)
	≥3	7 (24%)	4 (17%)
uT-Stage	T1	2 (7%)	2 (9%)	0.767#
	T2	2 (7%)	4 (17%)
	T3	18 (62%)	11 (48%)
	T4	3 (10%)	3 (13%)
	NA	4 (14%)	3 (13%)
uN-Stage	uN-	3 (10%)	4 (17%)	0.675#
	uN+	22 (76%)	15 (65%)
	NA	4 (14%)	4 (17%)
cM-Stage	cM0	23 (79%)	21 (91%)	0.234#
cM-Stage	cMX/1	6 (21%)	2 (9%)	0.234#
Grading	GX	11 (38%)	12 (52%)	0.362#
	G1	0 (0%)	1 (4%)
	G2	10 (34%)	7 (30%)
	G3	8 (28%)	3 (13%)
Neoadjuvant Chemotherapy		2 (7%)	0 (0%)	0.199#
Thereof: % FLOT		1 (50%)	0 (0%)
Neoadjuvant Chemoradiation		27 (93%)	23 (100%)
Thereof: % CROSS		23 (85%)	19 (83%)
Radiation Dosage (Gy) (n = 47)		41.1 (41.1–41.4)	41.1 (41.1–41.4)	0.558^*
Premature discontinuation of neoadjuvant treatment		2 (7%)	0 (0%)	0.199#
Days from end of neoadjuvant treatment to surgery (n = 51)		60 (45.5–84)	46.5 (37.75–59.75)	0.069^*
RECIST 1.1	CR/PR	21 (72%)	18 (78%)	0.629#
Procedure	2-Field-Esophagectomy	25 (86%)	23 (100%)	0.064#
	3-Field-Esophagectomy	4 (14%)	0 (0%)
	Transhiatal-extended gastrectomy	0 (0%)	0 (0%)
	Esophagogastrectomy	0 (0%)	0 (0%)
CCI (n = 52)		40.6 (26.1–60.2)	22.6 (0–62.6)	0.149^*
Length of Hospital Stay (days) (n = 52)		23 (16–27.5)	16 (13–24)	0.069^*
Pathological T-Stage	ypT0	4 (14%)	23 (100%)	<0.001#
	ypT1	6 (21%)	0 (0%)
	ypT2	10 (34%)	0 (0%)
	ypT3	8 (28%)	0 (0%)
	ypT4	1 (3%)	0 (0%)
Pathological N-Stage	ypN0	15 (52%)	23 (100%)	<0.001#
	ypN1	11 (38%)	0 (0%)
	ypN2	3 (10%)	0 (0%)
Tumor regression in lymphnodes in pCR-patients	(LN-/Reg+)/Grade A	NA	7 (30%)	NA
Tumor regression in lymphnodes in pCR-patients	(LN-/Reg-)	NA	16 (70%)	NA
Postneoadjuvant M-Stage	yM0	27 (93%)	23 (100%)	0.199#
Postneoadjuvant M-Stage	ypM1	2 (7%)	0 (0%)	0.199#
R-Status	R0	25 (86%)	23 (100%)	0.064#
R-Status	R1	4 (14%)	0 (0%)	0.064#
Postoperative UICC-Stage	UICC-Stage 0	0 (0%)	23 (100%)	<0.001#
	UICC-Stage I	7 (24%)	0 (0%)
	UICC-Stage II	11 (38%)	0 (0%)
	UICC-Stage III	8 (28%)	0 (0%)
	UICC-Stage IV	3 (10%)	0 (0%)
Histopathologic Regression	Grade 1a - No residual tumor	4 (14%)	23 (100%)	<0.001#
	Grade 1b – Subtotal regression (<10% residual tumor)	12 (41%)	0 (0%)
	Grade 2 – partial regression (10–50% residual tumor)	6 (21%)	0 (0%)
	Grade 3 – no regression (>50% residual tumor)	6 (21%)	0 (0%)
	Grade of regression not assessed	1 (3%)	0 (0%)

^*Mann–Whitney-U-test

^#Pearson’s chi squared-test

This Feature Is Available To Subscribers Only